![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/07/31/2921789/0/en/Immutep-Quarterly-Activities-Report-Q4-FY24.html
https://www.globenewswire.com/news-release/2024/07/22/2916491/0/en/Immutep-Announces-Successful-Meeting-with-FDA-on-Phase-III-Design-in-Non-Small-Cell-Lung-Cancer.html
https://www.globenewswire.com/news-release/2024/07/17/2914511/0/en/Immutep-Receives-Regulatory-Clearance-for-Phase-I-Study-of-First-in-Class-LAG-3-Agonist-Antibody-Designed-to-Treat-Autoimmune-Diseases.html
https://www.immutep.com/detail/immutep-reports-positive-results-in-first-line-head-and-neck-squamous-cell-carcinoma-patients-with-negative-pd-l1-expression.html
https://www.fiercebiotech.com/biotech/immutep-regains-pep-cancer-subgroup-data-show-path-forward-long-list-caveats
https://www.globenewswire.com/news-release/2024/07/11/2912179/0/en/Immutep-Reports-Positive-Results-in-First-Line-Head-and-Neck-Squamous-Cell-Carcinoma-Patients-with-Negative-PD-L1-Expression.html
https://www.globenewswire.com/news-release/2024/07/03/2908114/0/en/Immutep-Announces-Details-for-Oral-Presentation-at-ESMO-Virtual-Plenary-Session-and-Webcast-to-Discuss-Clinical-Results.html
https://www.biospectrumasia.com/news/26/24483/australias-immutep-signs-license-agreement-with-uk-based-cardiff-university-for-next-gen-cancer-drug.html
https://www.globenewswire.com/news-release/2024/06/25/2903718/0/en/Immutep-Signs-Exclusive-License-Agreement-with-Cardiff-University-for-Next-Generation-Anti-LAG-3-Molecules-for-Cancer.html
https://www.globenewswire.com/news-release/2024/06/05/2893680/0/en/Immutep-successfully-completes-institutional-placement-and-institutional-component-of-entitlement-offer.html